The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
Lymph nodes contain antibodies that undergo changes to their sequence as they adapt to their immune target, such as a flu virus. As this happens, the content of regulatory T cell (Treg) epitope sequences (also called Tregitopes) in the antibodies appears to decrease, which enables the B cells to expand and persist.
The study, " Regulatory T Cell Epitope Content in Human Antibodies Decreases During Maturation", was conducted by Andres Gutierrez, PhD and Annie De Groot, MD of EpiVax, using existing antibody sequence data. "This work provides important insights into how antibodies evolve over time, not just in terms of affinity, but in their ability to engage with the immune system." said Dr. Gutierrez.
The discovery of Tregitopes in 2008 marked a shift in awareness about the function of natural Tregs in human and animal immunity. Tregitopes may explain, in part, the tolerogenic impact of IV immunoglobulin therapy (IVIG). Tregitope-like peptides have since been found in other self-proteins.
A prior analysis of human antibody repertoires demonstrated that T cell epitopes decreased with increasing antibody maturation. However, that study didn't separate regulatory from effector T cell epitope dynamics. In this study, researchers examined antibody repertoires from four healthy human donors. They assessed three subsets of T cell epitopes: previously validated Tregitopes, potentially tolerated T cell epitopes and potential effector T cell epitopes.
Findings revealed that as antibodies mature and have higher affinity for their target antigen, Tregitope content systematically decreases, while potential effector T cell epitope content increases. This suggests that Tregitope depletion is a fundamental feature of antibody evolution. The observation was confirmed by testing some of the 'natural' and 'modified' Tregitope sequences in vitro.
"This mechanism is likely relevant to immunity from pathogens, to the development of autoantibodies during autoimmune disease, and for the selection of therapeutic antibody candidates", said Dr. De Groot. "We are pleased to contribute this finding to the literature on immune regulation and antibody design."
About EpiVax
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for therapeutics and vaccines. EpiVax collaborates with globally recognized partners to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 hours ago
- Korea Herald
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling — Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies — AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fat (commonly known as a "double chin"). This innovative injectable drug is designed to dramatically improve patient comfort by utilizing a novel biological mechanism that minimizes the pain and swelling commonly associated with existing treatments. A Paradigm Shift in Fat Reduction Therapy Currently, the only FDA-approved drug for localized fat reduction is based on deoxycholic acid, which destroys fat cells through necrosis —a process that induces inflammation and leads to significant side effects such as pain, bruising, and prolonged swelling. In contrast, AYP-101 is uniquely engineered to eliminate fat through apoptosis, a natural and controlled form of programmed cell death that does not trigger inflammation. This non-cytolytic mechanism offers a gentler, more tolerable alternative, potentially eliminating the need for social downtime and offering a safer, more comfortable experience for patients seeking non-surgical fat reduction. Phase 3 Trial Underway Following Strong Early Results The ongoing Phase 3 clinical trial involves 252 participants across multiple sites in South Korea and is expected to be completed by the end of 2025. The study builds on successful Phase 1 and 2 trials, which met all primary safety and efficacy endpoints. In the Phase 2 trial, over 70% of patients in the AYP-101 group achieved at least a 1-grade improvement on the Evaluator-Reported Submental Fat Rating Scale (ER-SMFRS) in the per-protocol (PP) population. The treatment also showed excellent tolerability and safety, with minimal adverse events reported. "AYP-101 represents the culmination of two decades of dedicated research aimed at creating a safe, effective, and globally competitive solution for localized fat reduction," said Ki-Taek Lee, CEO of AMI Pharm. "By leveraging a novel mechanism of action, we are pioneering the next generation of injectable drugs in aesthetic medicine." Targeting Global Expansion and Broader Indications AMI Pharm is actively preparing for global commercialization. The company is engaging international partners and showcasing its clinical data at world-renowned conferences, including the BIO International Convention and the IMCAS World Congress. While the current clinical focus is on submental fat, AMI Pharm is laying the groundwork to expand AYP-101's indications to address other high-demand aesthetic areas, including cellulite, deep buccal (cheek) fat, and upper arm fat. This broader R&D strategy highlights the company's commitment to addressing a wide spectrum of unmet needs in the aesthetic space and reinforces its ambition to become a global leader in non-surgical body contouring.
Korea Herald
4 days ago
- Korea Herald
Career-switching professionals, twins and trailblazers: Duke-NUS' Class of 2029 redefines path to medicine
SINGAPORE, Aug. 8, 2025 /PRNewswire/ -- A new chapter in Singapore's healthcare story began today as 78 aspiring doctors from Duke-NUS Medical School's 19th Doctor of Medicine (MD) cohort donned their white coats and recited the Hippocratic Oath, committing themselves to a future of medical excellence, professionalism and a lifelong service of healing. Duke-NUS' Class of 2029 reflects the School's bold and purposeful cultivation of medical talent—by welcoming individuals from a wide spectrum of academic and professional backgrounds. This year's students range in age from 22 to 33 and include 46 early-to-mid-career professionals who have switched paths to pursue medicine. Forming the School's largest batch of career-pivoting individuals, they bring with them rich perspectives from fields such as law, software engineering and economics. Also represented are fresh graduates from universities worldwide, as well as seven students admitted through Duke-NUS' conditional pathways in partnership with Singapore's top universities. Professor Thomas Coffman, Dean of Duke-NUS, said: "Duke-NUS was founded to reimagine how medical talent is developed in Singapore. By welcoming students with many academic backgrounds and life experiences, we bring together diverse minds united by a shared purpose—to serve, to heal and to improve health for generations to come. The White Coat Ceremony reflects our shared commitment for our students to become competent and compassionate doctors who may also contribute to medicine as scientists, educators, policy makers, innovators and future healthcare leaders." Along with their undergraduate degrees in a variety of fields, six members of the Class of 2029 hold Master's degrees and one has attained a PhD prior to joining the programme. Among the incoming students is Ms Seah Xue Er, Cheryl, 33, a former senior counsel with J. P. Morgan and a private legal practitioner with a decade of experience in law. Ms Seah, who has also taught yoga part-time, believes in competency and in being compassionate when caring for her patients. "I want to be a doctor who is hands-on, passionate and relentless in advocating for the best outcome for every patient. I would be someone who perseveres in the duty I have undertaken to provide the best care, treatment and recovery solution for them," she said. Another student, Ms Tania Chattopadhyay, 30, left a career in software engineering to pursue medicine—a dream she had wanted to fulfil since being inspired by her father's battle with a heart disorder. Now a mother, she is committed to engineering preventive health solutions in cardiovascular and metabolomic disorders treatment. "I believe many conditions can be detected early or even prevented altogether with the right tools, education and systems in place. I want to work on solutions that empower patients to take charge of their health and make care more proactive and effective," she said. This intake also includes the School's first pair of twin sisters, Ms Shruthi Kumar and Ms Swathi Kumar, 23, who studied psychology and engineering respectively and share a passion for healing. "Taking the next step into medicine together feels incredibly special—not just as a personal milestone but as a shared dream we've nurtured side by side," said Ms Shruthi Kumar, with Ms Swathi Kumar adding: "We've always challenged and supported each other, and now, we're excited to approach learning with different viewpoints and to bring our different strengths to medicine, together." Mr Tang Zheng Yang Tony, 24, an English Literature graduate who joined Duke-NUS via a conditional admissions pathway from Yale-NUS College, believes that medicine and literature are "two sides of the same coin" that illuminate the complexities of human life. He hopes to draw from the empathy and introspection instilled in him by his humanities training to offer holistic care as a clinician. "I have been blessed with many knowledgeable professors and a wealth of reading material that enliven me not just in an aesthetic sense, but also philosophically and spiritually, forming an important 'human' foundation for the medical profession," said Mr Tang, a recipient of the Duke-NUS Dean's Scholarship. The Class of 2029 includes 57 Singaporeans, four permanent residents and 17 international students from countries including China, the United States, the Philippines and India. All students will also undergo most of their clinical training at SingHealth institutions and graduate with an MD degree jointly awarded by Duke University and the National University of Singapore. Duke-NUS is the only graduate-entry medical school in Singapore. Its MD curriculum—rooted in research and team-based learning—caters to students who bring maturity, purpose and diverse experiences to medicine. About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
Korea Herald
6 days ago
- Korea Herald
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA ® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA ® IV in the United States. [1] Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19). [1] CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure. [2] "We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas." In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential. Notes to Editors: AVTOZMA ® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. INDICATION AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS INFECTIONS AVTOZMA ® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment. Contraindications: Known hypersensitivity to tocilizumab products. Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management. Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts. Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant. Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity. Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders. Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended. Live Vaccines. Avoid concurrent use with AVTOZMA. Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions. About Celltrion Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), STEQEYMA ® (ustekinumab-stba), and AVTOZMA ® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA ® (infliximab-dyyb). For more information, please visit Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
